• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.

作者信息

Kyle R A, Wagoner R D, Holley K E

出版信息

Arch Intern Med. 1982 Aug;142(8):1445-7. doi: 10.1001/archinte.142.8.1445.

DOI:10.1001/archinte.142.8.1445
PMID:7103624
Abstract

We describe two patients with primary systemic amyloidosis (AL) and the nephrotic syndrome. The administration of melphalan and prednisone was associated with resolution of the nephrotic syndrome. The serum albumin level returned to normal, proteinuria decreased to near normal, edema resolved, and the monoclonal protein in the serum and urine disappeared. In both patients, renal function remained stable and hepatomegaly disappeared. In both, however, amyloid deposition was greater in follow-up renal tissue than in the initial specimen. The effect of systemic therapy in AL must be assessed with histologic observations as well as clinical indexes.

摘要

相似文献

1
Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.
Arch Intern Med. 1982 Aug;142(8):1445-7. doi: 10.1001/archinte.142.8.1445.
2
Therapy of primary amyloidosis with melphalan and prednisone.美法仑和泼尼松治疗原发性淀粉样变性
Arch Intern Med. 1979 Oct;139(10):1144-7.
3
Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.化疗期间原发性淀粉样变性的消退。对一名肾病综合征患者的研究。
Ann Intern Med. 1975 Apr;82(4):466-73. doi: 10.7326/0003-4819-82-4-466.
4
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.采用剂量密集美法仑联合血干细胞支持治疗AL淀粉样变性:5例患者的一年随访
Blood. 1996 Oct 1;88(7):2801-6.
5
AL amyloidosis: therapeutic response in two patients with renal involvement.AL型淀粉样变性:两名肾脏受累患者的治疗反应
Nephrol Dial Transplant. 1991;6(8):592-4. doi: 10.1093/ndt/6.8.592.
6
Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
Blood. 1978 Oct;52(4):818-27.
7
Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
Arthritis Rheum. 1986 May;29(5):683-7. doi: 10.1002/art.1780290515.
8
A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival.一名患有多发性骨髓瘤、淀粉样变性和肾脏轻链沉积病且生存期较长的患者。
Acta Haematol. 1999;101(4):202-5. doi: 10.1159/000040954.
9
Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.大剂量静脉注射美法仑及自体血干细胞移植对AL淀粉样变性相关肾病的影响。
Ann Intern Med. 2001 May 1;134(9 Pt 1):746-53. doi: 10.7326/0003-4819-134-9_part_1-200105010-00011.
10
[Primary amyloidosis associated to severe factor X deficiency].[与严重因子X缺乏相关的原发性淀粉样变性]
Nefrologia. 2004;24(5):493-8.

引用本文的文献

1
Pathologic light chain amyloidosis oligomer detection in urinary extracellular vesicles as a diagnostic tool for response and progression of disease.尿细胞外囊泡中病理性轻链淀粉样寡聚体检测作为疾病反应和进展的诊断工具
Front Oncol. 2022 Oct 4;12:978198. doi: 10.3389/fonc.2022.978198. eCollection 2022.
2
Value of repeat renal biopsy in the evaluation of AL amyloidosis patients lacking renal response despite of complete hematologic remission: a case report and literature review.尽管完全血液学缓解,但缺乏肾脏反应的 AL 淀粉样变性患者重复肾活检的价值:病例报告及文献复习。
BMC Nephrol. 2022 Mar 31;23(1):127. doi: 10.1186/s12882-022-02752-4.
3
The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.
重复肾活检在系统性免疫球蛋白轻链淀粉样变性中的应用。
Amyloid. 2020 Mar;27(1):17-24. doi: 10.1080/13506129.2019.1672650. Epub 2019 Oct 9.
4
Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.含单唾液酸神经节苷脂的纳米脂质体可恢复由淀粉样轻链蛋白所致的内皮功能损伤。
J Am Heart Assoc. 2016 Jun 13;5(6):e003318. doi: 10.1161/JAHA.116.003318.
5
Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study.轻链(AL)淀粉样变性1年和长期死亡率的临床及影像学预测因素:一项5年随访研究
Heart Vessels. 2014 Nov;29(6):793-800. doi: 10.1007/s00380-013-0419-x. Epub 2013 Oct 19.
6
Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis.在 AL 淀粉样变性患者的肾活检标本中,肾功能与淀粉样蛋白阳性区域之间存在显著关联。
BMC Nephrol. 2012 Sep 24;13:118. doi: 10.1186/1471-2369-13-118.
7
Transthyretin (TTR) cardiac amyloidosis.转甲状腺素蛋白(TTR)心脏淀粉样变性
Circulation. 2012 Sep 4;126(10):1286-300. doi: 10.1161/CIRCULATIONAHA.111.078915.
8
Review of eprodisate for the treatment of renal disease in AA amyloidosis.依普罗沙坦治疗AA型淀粉样变性肾病的综述。
Int J Nephrol Renovasc Dis. 2012;5:37-43. doi: 10.2147/IJNRD.S19165. Epub 2012 Feb 24.
9
Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins.AL 淀粉样变性轻链蛋白诱导的人微血管功能障碍和细胞凋亡损伤。
Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2305-12. doi: 10.1152/ajpheart.00503.2011. Epub 2011 Sep 30.
10
Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture.免疫球蛋白轻链淀粉样变在细胞培养中的细胞毒性
Cell Death Dis. 2010 Nov 11;1(11):e98. doi: 10.1038/cddis.2010.75.